Use of L-alpha-lysophosphatidylcholine to obtain the differentiation of monocytes into mature dendritic cells in vitro
AssigneesBiomerieux, Institut National de la Sante et de la Recherche Medicale
InventorsVincent Lotteau, Patrice Andre
Life of this patent
Estimating the term…
Abstract
The disclosure relates to a method for in vivo differentiation of monocytes in mature dendritic cells, wherein a) monocytes are provided in an appropriate culture medium, b) the monocycles are differentiated in dendritic cells in the presence of a differentiation factor, c) L-α-lysophosphatidylcholine is added to the medium and mature dendritic cells are obtained. The disclosure also relates to the use of at least one inhibitor of L-α-lysophosphatidylcholine in the production of a medicament for the prevention of an inflammation and/or in order to combat an inflammatory disease and/or autoimmune disease.
Claims6
A method of treating and/or preventing, in a person, an infection of bacterial, viral, fungal or parasitic origin or an infection caused by a yeast, said method comprising administering L-α-lysophosphatidylcholine as an agent for activating the immune system of the person.
A method of treating or preventing cancer in a person, said method comprising administering L-α-lysophosphatidylcholine as an agent for activating the immune system of the person.
A vaccine composition, comprising:
- L-α-lysophosphatidylcholine as an agent for activating the immune system, and
- a biological agent.
A method for preventing an inflammation and/or for combating an inflammatory disease and/or an autoimmune disease in a person, said method comprising:
- administering to the person an inhibitor of L-α-lysophosphatidylcholine, in which the inhibitor is a lipid emulsion comprising triglycerides, phospholipids and glycerol.
A method for preventing an inflammation and/or for combating an inflammatory disease and/or an autoimmune disease in a person, said method comprising administering to the person an inhibitor of L-α-lysophosphatidylcholine, wherein the inhibitor is a PPARgamma agonist.
Dependencies are inferred from the claim text.